RevvityRVTYEarnings & Financial Report
Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.
RVTY Q1 FY2026 Key Financial Metrics
Revenue
$711.1M
Gross Profit
$387.7M
Operating Profit
N/A
Net Profit
$40.7M
Gross Margin
54.5%
Operating Margin
N/A
Net Margin
5.7%
YoY Growth
13.1%
Revvity Q1 FY2026 Financial Summary
Revvity reported revenue of $711.1M (up 13.1% YoY) for Q1 FY2026, with a net profit of $40.7M (up 361.2% YoY) (5.7% margin). Cost of goods sold was $323.5M.
Key Financial Metrics
| Total Revenue | $711.1M |
|---|---|
| Net Profit | $40.7M |
| Gross Margin | 54.5% |
| Operating Margin | N/A |
| Report Period | Q1 FY2026 |
Revvity Annual Revenue by Year
Revvity annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.9B).
Revvity Quarterly Revenue & Net Profit History
Revvity results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $711.1M | +13.1% | $40.7M | 5.7% |
| Q4 FY2025 | $772.1M | +5.9% | $98.4M | 12.7% |
| Q3 FY2025 | $698.9M | +2.2% | $46.7M | 6.7% |
| Q2 FY2025 | $720.3M | +4.1% | $53.9M | 7.5% |
| Q1 FY2025 | $664.8M | +2.3% | $42.2M | 6.4% |
| Q4 FY2024 | $729.4M | +8.7% | $94.6M | 13.0% |
| Q3 FY2024 | $684.0M | -3.5% | $94.4M | 13.8% |
| Q2 FY2024 | $691.7M | +2.5% | $55.4M | 8.0% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $691.7M | $684.0M | $729.4M | $664.8M | $720.3M | $698.9M | $772.1M | $711.1M |
| YoY Growth | 2.5% | -3.5% | 8.7% | 2.3% | 4.1% | 2.2% | 5.9% | 13.1% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $13.42B | $12.77B | $12.39B | $12.36B | $12.36B | $12.14B | $12.17B | $12.00B |
| Liabilities | $5.55B | $4.85B | $4.73B | $4.72B | $4.81B | $4.76B | $4.92B | $4.81B |
| Equity | $7.87B | $7.92B | $7.67B | $7.64B | $7.56B | $7.38B | $7.25B | $7.18B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $158.6M | $147.9M | $174.2M | $128.2M | $134.3M | $138.5M | $182.0M | $125.9M |